JAMA

💬 Viewpoint: US Medicaid cuts under the #OBBBA jeopardize #health coverage for millions of children, putting #pediatric care infrastructure and long-term societal well-being at risk. ja.ma/4haCFd6

📊 JAMA Research Summary: Among adults with early symptomatic #AlzheimerDisease, ceperognastat did not slow clinical decline, and higher doses increased adverse event rates. #AAIC26 @alzassociation ja.ma/4yqgVQT

Presented at #AAIC26: Meta-analysis: #Centiloid values <11 or >26 on #AmyloidPET scans provide high diagnostic confidence for the absence or presence of amyloid in #AlzheimerDisease, while values between 11 and 26 indicates uncertainty and may require further assessment. @alzassociation ja.ma/4pfm4H0

Presented at #AAIC26: In early symptomatic #AlzheimersDisease, #ceperognastat did not slow #clinical progression compared with placebo, and higher dose treatment led to more adverse events. ja.ma/4wJeeIs

💬 Editorial: The $35 #Insulin cap improved cost predictability and access for some Medicare users, but did not address racial and ethnic gaps or challenges from polypharmacy in #Diabetes care. #ADA2026 ja.ma/44P4kJg

Implementation of the $35 out-of-pocket cap for #Insulin among Medicare Part D users reduced average insulin costs and stabilized expenses, with increased use and adherence seen for patients with previously high out-of-pocket costs. #ADA2026 ja.ma/4ygZzWA

💬 Viewpoint: Recent regulatory changes allow osteoporosis drugs to be approved based on bone density rather than fractures, but long-term benefit and safety remain uncertain; improved patient education and prevention earlier in life are essential. ja.ma/4vpj1NT

Presented at #AAIC26 from @JAMANeuro: #Dementia prevalence increased over 2 decades in Mexico, Peru, and Puerto Rico, while rates remained stable in Cuba and the Dominican Republic, indicating an uneven and rising burden compared with high-income countries. ja.ma/44qjzZ6

Major scientific highlight from #ISTH2026 in Paris with simultaneous publication in @JAMA_current The RCT demonstrated that a diagnostic strategy using the YEARS algorithm in patients with cancer and suspected PE was as safe as using CTPA only, and decreased the need of diagnostic imaging by 22%. jamanetwork.com/journals/jama/…

Presented at #AAIC26: This clinicopathologic case report examined a patient with #Alzheimer disease and a p.R47H TREM2 variant who received long-term #aducanumab therapy. Postmortem analysis revealed that brain regions with extensive #amyloid clearance, particularly in gyral crests, displayed less #tau #pathology and slower atrophy on serial #MRI compared with regions where amyloid persisted. In contrast, regions with persistent amyloid, mostly in sulcal depths and deep cortical layers, showed typical tau burden and #neurodegeneration. @alzassociation 🔗 ja.ma/4bjfTfo

📊 JAMA Research Summary: Among adults with active #cancer and suspected #pulmonary #embolism, the YEARS algorithm safely excluded PE in 22% of cases, matching 90-day safety with computed tomographic pulmonary angiography-only management. ja.ma/4yiSrZD

💬 Editorial by Henry B. Han, MD, and Joshua A. Beckman, MD: The YEARS algorithm reduced CT pulmonary angiography use by 22% for suspected #PE in patients with cancer, meeting noninferiority safety benchmarks compared with imaging for all. #ISTH2026 ja.ma/4f6zG2H

Presented today at #ISTH2026: Among patients with #cancer and suspected #PE, use of the YEARS algorithm safely reduced CT #pulmonary #angiography, with 22% avoiding imaging and similar 90-day VTE rates to CTPA-only care. 🔗 ja.ma/4ydCSSY

In 2025, the number of #NIH-funded investigators declined for the first time in a decade, with the steepest reductions among Black and Hispanic researchers and fellows. ja.ma/4w2d8Yi

After Dobbs v Jackson, states with abortion bans saw more expectant management and less medication management for #miscarriage, with persistent reliance on misoprostol-only regimens. ja.ma/4aMZ5gL

#MedNews: A fentanyl vaccine is now in human trials. Could it be a breakthrough in overdose prevention? ja.ma/4yfJjoz

💬 Viewpoint: The #IOTA Model aims to boost kidney transplants but equity safeguards are limited. Ongoing monitoring, social risk–adjusted metrics, and requirements for transparent, accessible reporting are needed to ensure fair access. ja.ma/4fuGBEd

💬 Editorial by Henry B. Han, MD, and Joshua A. Beckman, MD: The YEARS algorithm reduced CT pulmonary angiography use by 22% for suspected #PE in patients with cancer, meeting noninferiority safety benchmarks compared with imaging for all. #ISTH2026 @isth ja.ma/4h8IAzn

📊 JAMA Research Summary: Among adults with active #cancer and suspected #pulmonary #embolism, the YEARS algorithm safely excluded PE in 22% of cases, matching 90-day safety with computed tomographic pulmonary angiography-only management. #ISTH2026 @isth ja.ma/44kZZgP

Application of the YEARS algorithm allowed 22% of patients to avoid CTPA, with no increase in missed venous #thromboembolism. These results suggest the YEARS algorithm provides a safe alternative to universal imaging in this population, warranting consideration in guideline recommendations and in settings where reducing CTPA use is a priority. 🔗 ja.ma/4y8ihzo #ISTH2026 @isth

Presented at #ISTH2026: In a multinational randomized clinical trial, the YEARS #algorithm was noninferior to CT #pulmonary #angiography (#CTPA) alone for ruling out acute pulmonary #embolism (PE) in patients with active #cancer. Among adults with suspected PE, the diagnostic failure rate was 1.8% for the YEARS arm and 5.5% for the CTPA-only arm over 90 days, with the upper bound of the confidence interval below the prespecified noninferiority margin. 🔗 ja.ma/4y8ihzo @isth